According to the World Health Organization (WHO), multidrug-resistant pathogens caused over 1.27 million deaths worldwide in ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...

JPMorgan Chase today announced new responsibilities for several senior executives as it continues to build on its leadership positions across global financial services. Daniel Pinto, President and ...

“We are delighted to announce that Radiance Biopharma was chosen to present at Biotech Showcase 2025 in San Francisco,” said Robert Brooks, JD, Chief Executive Officer, of Radiance. “We are eager to ...

JPMorgan Chase & Co.'s Chief Executive Jamie Dimon told analysts on Wednesday he plans to stay in the job "for a few more ...

The current head of the Center for Medicare has advice for her successor: "Engaging everyone in the ecosystem" is the ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

The bank said profit rose 50% to $14 billion in the fourth quarter as noninterest expenses fell 7% from a year earlier.

CFO Aradhana Sarin outlined AstraZeneca’s plans at the 2025 JP Morgan Healthcare Conference in San Francisco on 15 January.